For how we live.
Editor
Mac Giles is the editor of Health Newspapers and holds editorial responsibility for everything published here. His interests run across world news, health and wellness, and sport — the beats this paper spends most of its time on.
2,408 articles published to date. The 30 most recent are below.
An Ontario cohort of 1,035,927 pregnancies found excessive gestational weight gain was linked to more severe maternal morbidity in every BMI category, adjusted rate ratios 1.16 to 1.33 (observational).
I-SPY2.2 tested trastuzumab-deruxtecan plus rilvegostomig before surgery in high-risk HER2-negative breast cancer. In immune-positive tumours 54% had a complete response, and most of them avoided anthracyclines.
A Markov model of one U.S. birth cohort projects 255 chronic hepatitis B infections under universal birth-dose vaccination, rising 19% if the dose is deferred and 83% under shared decision-making (modelled).
A final FDA guidance treats the on-screen output of software sent with a prescription drug as a type of drug labelling, and says how the prescribing information should describe it and when sponsors submit it for review.
A surveillance analysis of WHO data from January 2024 to February 2026 tracks the clade Ib emergency from declaration to its end, and finds reported spread continued after the emergency was formally lifted.
A modelling study of Koungou village, calibrated to daily cases by vaccination status, estimates CVD 103-HgR prevented 87% of cholera and averted hundreds of cases — a first real-world test of a challenge-trial vaccine.
In a 98-patient French trial, six-monthly rituximab did not extend remission beyond daily azathioprine in this rare eosinophilic vasculitis — and recipients had more severe infections.
GSK's PD-1 blocker won accelerated US approval on 19 October for previously untreated stage II/III dMMR rectal cancer. In the single-arm AZUR-1 trial, most patients avoided surgery, radiation and chemotherapy.
A Global Burden of Disease analysis finds the share of female breast-cancer deaths tied to high fasting plasma glucose rose from 1990 to 2023 and is projected to keep rising — but the design cannot prove causation.
In 120 older adults with acute myeloid leukaemia, adding midostaurin to two-drug therapy did not raise remission rates overall (72% vs 68%), but a small FLT3-mutated subgroup lived longer.
In 108 people with Parkinson's, diffusion MRI found that damage to cholinergic pathways running from a deep-brain nucleus tracked worse cognition — and was most marked in those with dementia.
Pooling 19 studies, researchers found all-cause mortality raised about 1.7-fold in people with ADHD, with suicide and injury deaths most elevated — while those on ADHD medication had lower all-cause mortality.
A final FDA guidance sets out the safety information companies should provide when notifying the agency of a new dietary ingredient, replacing the old 'comprehensive safety profile' with a single 'safety narrative.'
A proposed rule would cut the Part D generic copay from $1 to $0 for the lowest-income dual eligibles in 2028, tighten Medicare Advantage directory accuracy, and add PBM transparency rules. Comments close 15 December.
A single-centre randomised trial found the Bergen 4-day treatment cut obsessive-compulsive symptoms far more than an unguided internet CBT programme, with 61% responding at three months versus 25%.
In 544 pregnant women followed across Rio de Janeiro state, adverse maternal outcomes hit 18% of confirmed Oropouche infections versus 7% without, with fetal loss and haemorrhage risks roughly tripled.
A 210-youth randomised trial of a telehealth aerobic-exercise program found faster symptom recovery at three months than stretching — an edge that disappeared by six months and held only for recent injuries.
In 425 US adolescents followed with phone sensors and Fitbits across 7,591 nights, heavier-than-usual late-evening phone use tracked with later, shorter sleep — the association growing hour by hour toward midnight.
In 143 people with poorly controlled type 1 diabetes, a system that prompts injections through glucose-sensor alerts was non-inferior to standard monitoring — and acting on the alerts drove the benefit.
A six-site randomised trial of point-of-care high-sensitivity troponin cut emergency-department length of stay by 47 minutes, with no change in 30-day heart attacks or cardiac deaths.
In 1,429 high-risk breast-cancer patients, a 16-dose regimen covering the internal mammary nodes matched the standard 25-dose course for recurrence and caused far less severe skin damage.
In 947 Chinese children followed for ten years, those with insulin resistance despite normal blood sugar had a 4.3-fold higher risk of later dysglycaemia, and six amino acids helped predict who would develop it.
In 1,095 high-risk abdominal-surgery patients, targeting each person's own cardiac index during the operation left the rate of major complications essentially unchanged — 44.3% versus 46.9%.
The FDA approved Tecentriq on 8 October, with chemotherapy, for Stage III mismatch repair deficient colon cancer after resection. In ATOMIC, adding it cut disease-free survival events, hazard ratio 0.50.
In nearly 40,000 UK women, abnormal blood pressure six weeks after a hypertensive pregnancy roughly doubled later cardiovascular disease. A Dutch cohort shows pregnancy history sharpens risk prediction.
Among 84 women on aromatase inhibitors, CO2 laser did no better than a fake laser for sexual function at 12 months. Both groups improved — on moisturisers and vibrators given to everyone.
In a 17-person phase 2a trial, once-weekly inhaled SPL84 lifted lung function in up to 70% of treated patients with the 3849+10 kb C→T mutation — a first reported clinical signal for an RNA-targeted inhaled therapy.
A cohort of 102 children born very preterm found epigenetic age acceleration linked to higher cognitive and motor scores at three — even, unexpectedly, in those with severe brain injury.
In 7,186 Korean adults followed up to 20 years, people flagged by fasting glucose, glucose tolerance and HbA1c all at once had a 15.3-fold higher risk of type 2 diabetes than normal controls.
LOTIS-9 tested loncastuximab tesirine plus rituximab in unfit and frail older adults with untreated DLBCL. Complete responses reached 53% and 42%, but severe side effects, including 11 deaths, ended the trial early.